azacitidine + rituximab + vincristine + cyclophosphamide

Azacitidine + rituximab + vincristine + cyclophosphamide is a multi-agent combination therapy under investigation for the treatment of diffuse large B-cell lymphoma (DLBCL), particularly in elderly or high-risk patients. Azacitidine is a DNA methyltransferase inhibitor that induces hypomethylation of DNA, leading to reactivation of tumor suppressor genes and inhibition of cancer cell proliferation. Rituximab is a monoclonal antibody targeting CD20 on B lymphocytes, promoting immune-mediated cytotoxicity against malignant B cells. Vincristine is an antimitotic agent that disrupts microtubule formation, arresting cell division and inducing apoptosis in rapidly dividing cells. Cyclophosphamide is an alkylating agent that crosslinks DNA strands, preventing replication and leading to cell death. This combination aims to leverage complementary mechanisms—epigenetic modulation, targeted immunotherapy, disruption of mitosis, and direct cytotoxicity—to improve outcomes in DLBCL[1][2][3][5][6].

Other names

CC-486 (for oral azacitidine)